Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure-Reference-Cited by-同舟云学术

Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure

Published:2023-08 Issue:4 Volume:21 Page:e286-e290
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Sanz Gómez Isabel^ORCID,Huguet Jorge,Bravo Alejandra,Robalino Jorge,Rodríguez Faba Óscar,Territo Ángelo,Gaya Josep María,Palou Joan,Breda Alberto

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference17 articles.

1. Emerging intravesical therapies for the management of bacillus Calmette–Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: charting a path forward;Chehroudi;Can Urol Assoc J,2020

2. Definition and management of patients with bladder cancer who fail BCG therapy;Martin;Expert Rev Anticancer Ther,2009

3. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG;Kamat;Nat Rev Urol,2017

4. A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Guérin unresponsive or recurrent/relapsing urothelial carcinoma of the bladder;DeCastro;J Urol,2020

5. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure;Juvet;Urol Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer;Expert Opinion on Pharmacotherapy;2024-07-02

2. Device-assisted intravesical chemotherapy versus bacillus Calmette–Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis;International Urology and Nephrology;2023-09-02